Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka

About this episode

Matias interviews Rob Malenka about the complexities and challenges in psychiatry and the potential of new therapies.

Matias interviews Rob Malenka. In this episode, we discuss: Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneousThe bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatryHow breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropyHow success depends on mission-driven, ethical peopl...

People in this episode

Host: Matias Serebrinsky

Guest: Rob Malenka

Topics covered

• psychiatry
• neuromodulation
• psychedelics
• bipolar disorder
• autism
• Parkinson's disease
• venture philanthropy

Keywords

• psychiatry
• neuromodulation
• psychedelics
• bipolar
• autism
• Parkinson's
• venture philanthropy
• research bottlenecks
• academic politics
• neuropsychiatry

Mentioned in this episode

Organizations: pharma, biotech, psychiatry, venture philanthropy

More episodes of Business Trip

• Brain Organoids: from Space to AI with Alysson Muotri · May 14, 2026 · 34 min
• How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics · March 25, 2026 · 26 min
• Inside Philanthropy’s Role in Mental & Brain Health · January 27, 2026 · 42 min
• Rick Perry on paving the way for Ibogaine in America · December 19, 2025 · 40 min
• Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute · November 24, 2025 · 49 min
• AI and the future of therapy with Luis Voloch of Jimini Health · October 16, 2025 · 38 min